{"entity":{"id":"nct03436485","kind":"trial","name":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","aka":["CYPIDES"],"tldr":"A phase 1/2 trial of Opevesostat in prostate cancer, run by Orion Corporation, Orion Pharma, active and no longer recruiting.","summary":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT03436485 by Orion Corporation, Orion Pharma, with 204 participants enrolled, started 2018-03-19 and due to reach its primary completion in 2026-10-31. Interventions recorded: ODM-208, Midazolam. Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03436485","url":"https://clinicaltrials.gov/study/NCT03436485"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["opevesostat"],"companies":["orion-orion-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03436485-nejm-evid-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03436485","phase":"1/2","setting":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","sponsor":"Orion Corporation, Orion Pharma","started":"2018-03-19","startedType":"actual","enrolled":204,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03436485/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/"}],"company":[{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/"}],"paper":[{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/"}]}}